Form 8-K - Current report:
SEC Accession No. 0001477932-22-001739
Filing Date
2022-03-30
Accepted
2022-03-30 16:14:00
Documents
15
Period of Report
2022-03-30
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K vnrx_8k.htm   iXBRL 8-K 23161
2 PRESS RELEASE vnrx_ex991.htm EX-99.1 48880
  Complete submission text file 0001477932-22-001739.txt   207564

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vnrx-20220330.xsd EX-101.SCH 5830
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vnrx-20220330_lab.xml EX-101.LAB 14819
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE vnrx-20220330_cal.xml EX-101.CAL 898
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vnrx-20220330_pre.xml EX-101.PRE 9398
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vnrx-20220330_def.xml EX-101.DEF 2103
9 EXTRACTED XBRL INSTANCE DOCUMENT vnrx_8k_htm.xml XML 3597
Mailing Address 13215 BEE CAVE PARKWAY GALLERIA OAKS B, SUITE 125 AUSTIN TX 78738
Business Address 13215 BEE CAVE PARKWAY GALLERIA OAKS B, SUITE 125 AUSTIN TX 78738 1 (646) 650-1351
VOLITIONRX LTD (Filer) CIK: 0000093314 (see all company filings)

EIN.: 911949078 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36833 | Film No.: 22786616
SIC: 2835 In Vitro & In Vivo Diagnostic Substances